In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson's treatment and more.
Read the full coverage here:
Evaluate headache characteristics to classify as migraine
FDA grants breakthrough device designation for brain implant technology
New genetic engineering company aims to develop neuroactive compounds from plants, fungi
Angiotensin receptor blocker therapy associated with decreased incidence of epilepsy
Theranica announces positive results from clinical trial for migraine treatment device
References:
Diamond M. Migraine, chronic migraine and medication overuse headache: Where are we today? Presented at: PAINWeek; Sept. 6-9, 2022; Las Vegas
Doege C, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3413.
